How to Choose a Vaccine Manufacturing Partner

The short answer: Choosing a vaccine manufacturing partner starts with platform fit — mRNA, viral vector, protein subunit, inactivated and conjugate vaccines are effectively different factories, and a CDMO excellent at one is rarely credible at another. After platform, weigh scale and surge capacity (vaccines are volume products, and outbreak demand is spiky), cold-chain capability (mRNA needs ultra-low-temperature handling that most sites cannot provide), and — the part buyers most often under-plan — sterile fill–finish at scale, which is the common bottleneck. As with any injectable, weight the site's GMP and inspection record heavily, because a sterility failure in a vaccine is among the most serious outcomes in manufacturing.

Vaccines combine two hard problems: a biologically complex product and public-health-scale volume, often under time pressure. That makes partner selection a platform decision first and a capacity decision second, and it makes the sterile fill–finish step — the one that turns bulk antigen into millions of doses in vials or syringes — the constraint that most often determines whether supply actually reaches patients.

Platform first: match the factory to the vaccine

The single biggest determinant of fit is the vaccine platform, because each uses a different production process, facility and skill set:

• mRNA — an in-vitro transcription and lipid-nanoparticle (LNP) formulation process, plus demanding ultra-cold handling. A relatively young manufacturing discipline with a short list of genuinely experienced partners.
• Viral vector (adenoviral, and related) — cell-culture upstream and a complex purification train, closer to a biologics problem.
• Protein subunit / recombinant — expression, purification and often adjuvant formulation.
• Conjugate and polysaccharide vaccines — chemistry-heavy conjugation steps.
• Inactivated / live-attenuated — traditional egg- or cell-based culture at large scale.

Ask for evidence in your platform specifically — programs taken through the clinic or to licensure — not a general "we make vaccines." The platform gap is where the most expensive mismatches happen.

1. Assess scale and surge capacity

Vaccines are volume products, and demand is rarely smooth:

• Commercial-scale capacity matched to a public-health forecast, which is larger than most therapeutic programs.
• Surge and flexibility — the ability to expand output quickly for an outbreak or campaign, which is a real differentiator for pandemic-relevant products.
• Single-use vs stainless trade-offs (as in biologics) that suit either flexible multi-product use or large fixed volumes.

A partner sized for a therapeutic biologic may simply not have the throughput a vaccine program needs.

2. Confirm cold-chain and stability handling

Cold chain is a first-order requirement, not logistics detail:

• mRNA products can require ultra-low-temperature storage and handling throughout manufacture and fill — a capability most fill–finish sites do not have.
• Container-closure and stability work appropriate to the storage profile you are targeting.
• Alignment between the CDMO's cold-chain capability and your target product profile, so you are not designing a vaccine you cannot actually fill and ship.

3. Plan the fill-finish bottleneck deliberately

This is the step buyers most often under-plan. Bulk antigen is not doses; the aseptic fill of vials or prefilled syringes at vaccine scale is a specialised, capacity-constrained discipline governed by the same high sterile-GMP standards (EU Annex 1) as any injectable. Confirm:

• High-throughput sterile fill capacity in your format, with modern barrier technology,
• Successful aseptic process simulations (media fills) and a clean sterility-assurance record, and
• either in-house fill or a planned, proven transfer from your antigen partner — not an improvised hand-off at launch.

Under-scoping fill–finish is the classic way a vaccine with good bulk supply still fails to reach patients on time.

4. Weight the regulatory and inspection record

Vaccines carry heavy regulatory scrutiny — lot release, dedicated inspections, and, for a sterile injectable, the highest compliance bar. Confirm the CDMO has taken a comparable platform through licensure and passed inspections of the relevant site, and check that site's FDA Form 483, Warning Letter and recall record as a pattern. For a product given to healthy people at population scale, a weak compliance history is disqualifying.

Common pitfalls

• Buying capacity without platform fit — mRNA and viral-vector experience do not transfer.
• Treating cold chain as logistics rather than a manufacturing constraint that shapes what you can fill.
• Under-planning fill–finish, then finding bulk antigen has no route to doses at scale.
• Ignoring surge needs for a product whose demand can spike overnight.

Where this fits

Vaccine sourcing is CDMO selection applied to a platform-defined, high-volume, high-compliance product — biologics-style upstream questions combined with a sterile fill–finish constraint. If you are weighing integrated development versus pure manufacturing, start with CRO vs CDMO vs CMO.

PharmaTek links CDMO and fill–finish capabilities to each company's GMP and FDA compliance record across a directory of 22,000+ pharmaceutical companies and manufacturers, so a vaccine shortlist can be built for platform fit and screened for compliance at once.

Frequently asked questions

What is the most important factor when choosing a vaccine CDMO? Platform fit. mRNA, viral vector, protein subunit, conjugate and inactivated vaccines each use a different production process, facility and skill set, so the priority is a partner with demonstrated experience in your platform. Scale and surge capacity, cold-chain capability, and sterile fill–finish come next — with fill–finish often the real capacity bottleneck.

Why is fill-finish the bottleneck in vaccine manufacturing? Because turning bulk antigen into millions of sterile doses in vials or syringes is a specialised, capacity-constrained, high-compliance step governed by strict sterile-GMP standards (EU Annex 1). Many programs secure bulk supply but under-plan aseptic fill capacity in the right format, so the vaccine cannot reach patients at scale on time. Plan the fill step — in-house or via a proven transfer — deliberately.

What cold-chain capability should a vaccine manufacturer have? It depends on the platform. mRNA vaccines can require ultra-low-temperature storage and handling throughout manufacture and fill, which most sites do not offer, while other platforms have less demanding profiles. Confirm the CDMO's cold-chain and stability handling matches your target product profile so you are not designing a vaccine you cannot actually fill and ship.

Does mRNA vaccine manufacturing need a specialist CDMO? Generally yes. mRNA manufacturing (in-vitro transcription plus lipid-nanoparticle formulation) is a relatively young discipline with a short list of genuinely experienced partners and demanding ultra-cold handling. Experience in other biologics or vaccine platforms does not transfer directly, so seek demonstrated mRNA-specific programs.

How much does surge capacity matter for a vaccine partner? For pandemic- or campaign-relevant vaccines, a great deal. Demand can spike quickly, so the ability to expand output at short notice is a real differentiator. Match the CDMO's commercial-scale capacity and flexibility to a public-health forecast, which is typically larger and spikier than a therapeutic program's.

---

Sourcing a vaccine manufacturing partner? Explore the supplier directory or book a demo to screen candidates against live GMP and FDA compliance data.